90 related articles for article (PubMed ID: 2165448)
1. FDA approves marketing of cytomegalovirus immune globulin.
Clin Pharm; 1990 Jul; 9(7):493. PubMed ID: 2165448
[No Abstract] [Full Text] [Related]
2. Cost-effective use of cytomegalovirus immune globulin in recipients of orthotopic liver transplants.
Uber LA
Am J Hosp Pharm; 1994 Nov; 51(22):2843, 2846. PubMed ID: 7856614
[No Abstract] [Full Text] [Related]
3. From the Food and Drug Administration.
Nightingale SL
JAMA; 1990 Jul; 264(2):168. PubMed ID: 2162399
[No Abstract] [Full Text] [Related]
4. Incidence of infection and acute rejection after cytomegalovirus immune globulin prophylaxis in renal transplantation.
Basadonna G; Feria A; Perez R; Klein H; Sturges M; Colquhoun S
Transplant Proc; 1994 Oct; 26(5 Suppl 1):52-3. PubMed ID: 7940976
[No Abstract] [Full Text] [Related]
5. Elimination of cytomegalovirus disease in liver transplant patients treated prophylactically with combination cytomegalovirus hyperimmune globulin and ganciclovir.
Prian GW; Koep LJ
Transplant Proc; 1994 Oct; 26(5 Suppl 1):54-5. PubMed ID: 7940977
[No Abstract] [Full Text] [Related]
6. A further analysis of the use of cytomegalovirus immune globulin in orthotopic liver transplant patients at risk for primary infection. Boston Center for Liver Transplantation CMVIG-Study Group.
Snydman DR; Werner BG; Dougherty NN; Griffith J; Rohrer RH; Freeman R; Jenkins R; Lewis WD; O'Rourke E
Transplant Proc; 1994 Oct; 26(5 Suppl 1):23-7. PubMed ID: 7940972
[No Abstract] [Full Text] [Related]
7. FDA approves cidofovir for treatment of CMV retinitis. Food and Drug Administration.
J Int Assoc Physicians AIDS Care; 1996 Aug; 2(8):30. PubMed ID: 11363758
[TBL] [Abstract][Full Text] [Related]
8. Consensus conference evaluates key issues concerning use of intravenous immune globulin.
Clin Pharm; 1990 Jul; 9(7):489, 492-3. PubMed ID: 2198122
[No Abstract] [Full Text] [Related]
9. FDA approves marketing of diclofenac.
Clin Pharm; 1988 Nov; 7(11):785. PubMed ID: 3197378
[No Abstract] [Full Text] [Related]
10. Diabetes technology news. FDA approves CYPHER Stent.
Walczak IM
Diabetes Technol Ther; 2003; 5(3):509-10. PubMed ID: 12838934
[No Abstract] [Full Text] [Related]
11. FDA notifications. FDA approves generic foscarnet sodium injection.
AIDS Alert; 2005 Jul; 20(7):82. PubMed ID: 16110563
[No Abstract] [Full Text] [Related]
12. Immune globulin therapy in allogeneic bone marrow transplant: a critical review.
Guglielmo BJ; Wong-Beringer A; Linker CA
Bone Marrow Transplant; 1994 May; 13(5):499-510. PubMed ID: 8054903
[TBL] [Abstract][Full Text] [Related]
13. Revision of requirements applicable to albumin (human), plasma protein fraction (human), and immune globulin (human). Food and Drug Administration, HHS. Final rule.
Fed Regist; 2000 Aug; 65(167):52016-8. PubMed ID: 11067735
[TBL] [Abstract][Full Text] [Related]
14. FDA approves generic AZT for U.S. market.
O'Rourke M
AIDS Clin Care; 2005 Nov; 17(11):108. PubMed ID: 16323302
[No Abstract] [Full Text] [Related]
15. Cytomegalovirus immune globulin (CMVIG) prophylaxis is associated with increased survival after orthotopic liver transplantation. The Boston Center for Liver Transplantation CMVIG Study Group.
Falagas ME; Snydman DR; Ruthazer R; Griffith J; Werner BG; Freeman R; Rohrer R
Clin Transplant; 1997 Oct; 11(5 Pt 1):432-7. PubMed ID: 9361936
[TBL] [Abstract][Full Text] [Related]
16. FDA approves marketing of octreotide.
Clin Pharm; 1989 Jan; 8(1):4. PubMed ID: 2912662
[No Abstract] [Full Text] [Related]
17. Availability of immune globulin intravenous for treatment of immune deficient patients--United States, 1997-1998.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 1999 Mar; 48(8):159-62. PubMed ID: 10079062
[TBL] [Abstract][Full Text] [Related]
18. FDA approves restricted marketing of Lotronex.
FDA Consum; 2002; 36(4):4. PubMed ID: 12184306
[No Abstract] [Full Text] [Related]
19. A further analysis of primary cytomegalovirus disease prevention in renal transplant recipients with a cytomegalovirus immune globulin: interim comparison of a randomized and an open-label trial.
Snydman DR; Werner BG; Tilney NL; Kirkman RL; Milford EL; Cho SI; Bush HL; Levey AS; Strom TB; Carpenter CB
Transplant Proc; 1988 Dec; 20(6 Suppl 8):24-30. PubMed ID: 2849222
[No Abstract] [Full Text] [Related]
20. Incidence of cytomegalovirus infection and effects of cytomegalovirus immune globulin prophylaxis after orthotopic liver transplantation.
Saliba F; Gugenheim J; Samuel D; Bismuth A; Mathieu D; Serres C; Bismuth H
Transplant Proc; 1987 Oct; 19(5):4081-2. PubMed ID: 2823435
[No Abstract] [Full Text] [Related]
[Next] [New Search]
